Stock Price
2.17
Daily Change
-0.18 -7.66%
Monthly
-3.98%
Yearly
69.53%
Q2 Forecast
2.13

Galectin Therapeutics reported $-83.87M in Equity Capital and Reserves for its fiscal quarter ending in June of 2024.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Galectin Therapeutics USD -83.87M 11.06M Jun/2024
Gilead Sciences USD 23.52B 897M Mar/2026
Immunic USD 151.23M 157.91M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Merck USD 45.88B 6.73B Mar/2026